Trial abstracts in the registry — page 16
700 documents of type trial abstract.
Documents
-
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 911 participants over 26 weeks. Primary result: Did not meet…
High08 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low07 Jul 2023 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and obesity randomising 529 participants over 52 weeks. Primary result: Clinical…
Moderate05 Jul 2023 -
Randomised crossover, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jul 2023 -
Observational, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low04 Jul 2023 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low04 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low03 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low02 Jul 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Semaglutide in type 2 diabetes randomising 1,201 participants over 40 weeks. Primary result: Difference…
High01 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low30 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported…
Very low29 Jun 2023 -
Randomised crossover, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low29 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 377 participants over 30 weeks. Primary result: Reduction of…
High28 Jun 2023 -
Observational, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jun 2023 -
Single-arm open-label, phase 2 study of Thymosin beta-4 in wound healing over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low23 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low23 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 1/2 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low17 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Jun 2023 -
Single-arm open-label, phase 3 study of Lixisenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low16 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low16 Jun 2023 -
Observational, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low13 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low13 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 475 participants over 40 weeks. Primary result: Reduction of…
High12 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low12 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low12 Jun 2023 -
Randomised crossover, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 Jun 2023 -
Single-arm open-label, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low11 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low10 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low08 Jun 2023
page 16 of 18